Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5

US9926379B2 · kind B2 · utility

Assignee

• Roche Glycart AG · CH

Inventors

• Peter Bruenker · Hittnau, CH
• Sherif Daouti · Totowa, US
• Ningping Feng · King City, CA
• Claudia Ferrara Koller · Schlieren, CH
• Guy Georges · Habach, DE
• Sandra Grau-Richards · Schlieren, CH
• Ralf Hosse · Baar, CH
• Christian Klein · Iffeldorf, DE
• Maximiliane Koenig · Pullach, DE
• Joerg Moelleken · Penzberg, DE
• Ekkehard Moessner · Kreuzlingen, CH
• Huifeng Niu · Scotch Plains, US
• Kathryn Packman · Newton, US
• Valeria Runza · Penzberg, DE
• Stefan Seeber · Penzberg, DE
• Pablo Umana · Wollerau, CH
• Inja Waldhauer · Schlieren, CH
• Huisheng Wang · Edison, US
• Barbara Weiser · East Greenbush, US

Key dates

• Filing date: Apr 1, 2014
• Grant date: Mar 27, 2018
• Expiry date: Jul 12, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.